Extracellular Traps: A Novel Therapeutic Target for Severe Asthma
Youngwoo Choi,Quoc Quang Luu,Hae-Sim Park
DOI: https://doi.org/10.2147/JAA.S366014
2022-06-15
Journal of Asthma and Allergy
Abstract:Youngwoo Choi, 1 Quoc Quang Luu, 1, 2 Hae-Sim Park 1, 2 1 Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea; 2 Department of Biomedical Sciences, Graduate School of Ajou University, Suwon, Korea Correspondence: Hae-Sim Park, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, 164 Worldcup-ro, Suwon, Korea, Tel +82-31-219-5000, Fax +82-31-219-6380, Email Asthma is a complicated disease defined by a combination of clinical symptoms and physiological characteristics. Typically, asthma is diagnosed by the presence of episodic cough, wheezing, or dyspnea triggered by variable environmental factors (allergens and respiratory infections), and reversible airflow obstruction. To date, the majority of asthmatic patients have been adequately controlled by anti-inflammatory/bronchodilating agents, but those with severe asthma (SA) have not been sufficiently controlled by high-dose inhaled corticosteroids-long-acting beta-agonists plus additional controllers including leukotriene modifiers. Accordingly, these uncontrolled patients provoke a special issue, because they consume high healthcare resources, requiring innovative precision medicine solutions. Recently, phenotyping based on biomarkers of airway inflammation has led to elucidating the pathophysiological mechanism of SA, where emerging evidence has highlighted the significance of eosinophil or neutrophil extracellular traps contributing to the development of SA. Here, we aimed to provide current findings about extracellular traps as a novel therapeutic target for asthma to address medical unmet needs. Keywords: asthma, eosinophil, extracellular trap, neutrophil, therapeutics, unmet needs Asthma is well known as a chronic airway inflammatory disease with variable airway obstruction. Currently, approximately 300 million people worldwide suffer from asthma and more than 400 million will be affected by 2025. 1 In particular, the prevalence of asthma tends to increase in low- and high-income countries. Asthmatic patients have typical asthma symptoms as well as the evidence of reversible airflow obstruction evaluated by spirometry and bronchodilator test. Among them, patients with severe asthma (SA, accounting for 10% of asthmatic patients) suffer from more frequent asthma exacerbations even on maintaining high-dose inhaled corticosteroids (ICSs). 2,3 Moreover, SA could affect patients throughout ages from child to adult. 4 To date, many efforts to classify asthma phenotypes, 5,6 identify various biomarkers, 7 and develop multiple therapeutic agents 8 have been made to manage SA. Nevertheless, a growing need to find a unique target for asthma treatment is increasing because some patients with SA still remains uncontrolled. Recently, circulating eosinophil extracellular traps (EETs) and neutrophil extracellular traps (NETs) have been highlighted as novel biomarkers for SA. 9 Moreover, these molecules containing DNAs and granule proteins have been suggested to enhance airway inflammation related to asthma severity. Therefore, this review mainly focused on discussing future directions for new therapeutic targets by understanding pathophysiological mechanisms of SA related to extracellular trap formation. Up to now, many definitions of SA have been suggested worldwide. 10,11 The European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines define SA as asthma that requires treatment with high-dose ICSs plus second controller medications and/or systemic corticosteroids to maintain asthma control or that remains uncontrolled despite the aforementioned medications (having asthma exacerbation more than 2 times per year). However, the recent Global Initiative for Asthma (GINA) guideline defines SA if asthma is uncontrolled despite adherence to maximal optimized therapy (step 4/5 treatment including medium-to-high-dose ICSs plus second controllers and/or systemic corticosteroids) and management of comorbid conditions. 10,11 Based on current clinical control status and risk factors, the World Health Organization has also defined SA as uncontrolled asthma which can result in the risk of frequent severe exacerbations (or death), adverse reactions to medications, and/or chronic morbidity. 12 Asthma has been described from various points of view, characterizing comorbidities, microbial composition, viral infections, and inflammatory status. 13 Especially, SA can be broadly classified into 2 major phenotypes including T2-high and T2-low asthma, although it shows more diverse phenotypes with complexity. Patients with T2-high asthma show persistent blood or sputum eosinophilia even with maintaining anti-inflam -Abstract Truncated-
immunology,allergy,respiratory system